DK2425815T3 - Stabiliseret farmaceutisk submikrometersuspensioner og fremgangsmåder til fremstilling deraf - Google Patents

Stabiliseret farmaceutisk submikrometersuspensioner og fremgangsmåder til fremstilling deraf

Info

Publication number: DK2425815T3
Authority: DK; Denmark
Prior art keywords: submicrometer; suspensions; preparation; methods; submicron suspension
Prior art date: 2008-09-19

Application number

DK11191277.0T

Other languages

English (en)

Inventor

Ernesto J Castillo

Bahram Asgharian

Masood A Chowhan

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-19

Filing date

2009-09-16

Publication date

2018-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2425815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-16 Application filed by Novartis Ag filed Critical Novartis Ag

2018-01-29 Application granted granted Critical

2018-01-29 Publication of DK2425815T3 publication Critical patent/DK2425815T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK11191277.0T 2008-09-19 2009-09-16 Stabiliseret farmaceutisk submikrometersuspensioner og fremgangsmåder til fremstilling deraf DK2425815T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9828008P	2008-09-19	2008-09-19
EP09792581.2A EP2328551B1 (en)	2008-09-19	2009-09-16	Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Publications (1)

Publication Number	Publication Date
DK2425815T3 true DK2425815T3 (da)	2018-01-29

Family

ID=41353867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11191277.0T DK2425815T3 (da)	2008-09-19	2009-09-16	Stabiliseret farmaceutisk submikrometersuspensioner og fremgangsmåder til fremstilling deraf

Country Status (26)

Country	Link
US (3)	US20100076045A1 (da)
EP (2)	EP2425815B1 (da)
JP (3)	JP5739809B2 (da)
KR (1)	KR101682924B1 (da)
CN (2)	CN102176898A (da)
AR (2)	AR073597A1 (da)
AU (1)	AU2009293400B2 (da)
BR (1)	BRPI0919199B8 (da)
CA (1)	CA2736106C (da)
CL (1)	CL2009001856A1 (da)
CY (1)	CY1119740T1 (da)
DK (1)	DK2425815T3 (da)
ES (2)	ES2657455T3 (da)
HR (1)	HRP20180050T1 (da)
HU (1)	HUE037933T2 (da)
LT (1)	LT2425815T (da)
MX (1)	MX348204B (da)
NO (1)	NO2425815T3 (da)
PL (2)	PL2425815T3 (da)
PT (2)	PT2425815T (da)
RU (1)	RU2521258C2 (da)
SI (1)	SI2425815T1 (da)
TW (1)	TWI580441B (da)
UY (1)	UY32095A (da)
WO (1)	WO2010033528A1 (da)
ZA (1)	ZA201101398B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070202186A1 (en)	2006-02-22	2007-08-30	Iscience Interventional Corporation	Apparatus and formulations for suprachoroidal drug delivery
US20100234469A1 (en) *	2009-03-12	2010-09-16	Medichem, S.A.	New Crystals Of A Benzoylbenzeneacetamide Derivative
CN106214321B (zh)	2010-10-15	2018-08-28	科尼尔赛德生物医学公司	用于进入眼睛的装置
AU2011340174A1 (en) *	2010-12-06	2013-07-25	Degama Berrier Ltd.	Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US9056057B2 (en)	2012-05-03	2015-06-16	Kala Pharmaceuticals, Inc.	Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en)	2012-05-03	2020-11-18	Kala Pharmaceuticals, Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
KR102373259B1 (ko) *	2012-05-03	2022-03-17	칼라 파마슈티컬스, 인크.	개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
CN105007898A (zh) *	2012-12-19	2015-10-28	卡希夫制药有限责任公司	难溶性药物的过饱和的稳定纳米颗粒
EP2956138B1 (en)	2013-02-15	2022-06-22	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es)	2013-02-20	2021-06-09	Kala Pharmaceuticals Inc	Compuestos terapéuticos y sus usos
CN105246529B (zh)	2013-05-03	2019-06-14	科尼尔赛德生物医学公司	用于眼部注射的设备和方法
CN108530458A (zh)	2013-11-01	2018-09-14	卡拉制药公司	治疗化合物的结晶形式及其用途
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2016036588A1 (en) *	2014-09-03	2016-03-10	Merck Sharp & Dohme Corp.	Pharmaceutical suspensions containing etoricoxib
JP2019514581A (ja)	2016-05-02	2019-06-06	クリアサイドバイオメディカル，インコーポレイテッド	眼の薬物送達のためのシステムおよび方法
CN110177527B (zh)	2016-08-12	2022-02-01	科尼尔赛德生物医学公司	用于调节药剂递送用针的插入深度的装置和方法
EP3509421A4 (en)	2016-09-08	2020-05-20	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en)	2016-09-08	2019-04-09	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018053318A1 (en) *	2016-09-16	2018-03-22	Kala Pharmaceuticals, Inc.	Particles, compositions, and methods for ophthalmic and/or other applications
WO2020214799A1 (en) *	2019-04-16	2020-10-22	Clearside Biomedical, Inc.	Injectable triamcinolone formulations
WO2025183017A1 (ja) *	2024-02-26	2025-09-04	大塚製薬株式会社	Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5466680A (en) *	1992-03-26	1995-11-14	Cytologics, Inc.	Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) *	1992-10-07	1996-08-01	Cusi Lab	Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) *	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) *	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
WO1995005803A1 (en) *	1993-08-20	1995-03-02	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
US5718919A (en) *	1995-02-24	1998-02-17	Nanosystems L.L.C.	Nanoparticles containing the R(-)enantiomer of ibuprofen
US6428814B1 (en) *	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) *	2000-09-21	2002-04-23	Elan Pharma International Ltd.	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) *	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
ATE389455T1 (de) *	2000-05-10	2008-04-15	Jagotec Ag	Zerkleinerung mittels mahlkörper
PE20020146A1 (es) *	2000-07-13	2002-03-31	Upjohn Co	Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) *	2002-01-08	2003-12-27	Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН	Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) *	2002-03-27	2006-11-21	University Of Southern Mississippi	Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
AU2003261167A1 (en) *	2002-07-16	2004-02-02	Elan Pharma International, Ltd	Liquid dosage compositions of stable nanoparticulate active agents
CA2513006A1 (en) *	2003-01-15	2004-08-05	Dow Global Technologies Inc.	Drug particles obtained by freezing onto a cold surface
US20040235892A1 (en)	2003-05-22	2004-11-25	Yujia Dai	Indazole and benzisoxazole kinase inhibitors
MXPA06003185A (es) *	2003-09-23	2006-06-23	Alcon Inc	Formulaciones de acetonuro de triamcinolona y de acetato de anecotarve para inyeccion.
US20060141049A1 (en) *	2003-11-12	2006-06-29	Allergan, Inc.	Triamcinolone compositions for intravitreal administration to treat ocular conditions
EP1713514B1 (en) *	2004-01-28	2021-11-24	Johns Hopkins University	Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) *	2004-10-19	2006-04-27	Pfizer Inc.	Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) *	2004-12-08	2006-06-15	Merck & Co., Inc.	Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en)	2005-02-23	2006-12-01	Alcon Inc	Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
JP2008535924A (ja) *	2005-04-12	2008-09-04	エランファーマインターナショナルリミテッド	ナノ粒子キナゾリン誘導体製剤
CA2603189A1 (en) *	2005-04-13	2006-10-19	Pfizer Products Inc.	Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) *	2005-07-22	2011-02-22	Oculis Ehf	Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) *	2005-09-30	2013-01-09	富山化学工業株式会社	難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007076448A2 (en) *	2005-12-23	2007-07-05	Alcon, Inc.	Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070196350A1 (en) *	2006-02-22	2007-08-23	Bartels Stephen P	Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

2009
- 2009-09-03 TW TW098129672A patent/TWI580441B/zh active
- 2009-09-07 UY UY0001032095A patent/UY32095A/es not_active Application Discontinuation
- 2009-09-15 CL CL2009001856A patent/CL2009001856A1/es unknown
- 2009-09-16 ES ES11191277.0T patent/ES2657455T3/es active Active
- 2009-09-16 CA CA2736106A patent/CA2736106C/en active Active
- 2009-09-16 MX MX2011002494A patent/MX348204B/es active IP Right Grant
- 2009-09-16 AR ARP090103553A patent/AR073597A1/es not_active Application Discontinuation
- 2009-09-16 PT PT111912770T patent/PT2425815T/pt unknown
- 2009-09-16 LT LTEP11191277.0T patent/LT2425815T/lt unknown
- 2009-09-16 PT PT97925812T patent/PT2328551T/pt unknown
- 2009-09-16 EP EP11191277.0A patent/EP2425815B1/en active Active
- 2009-09-16 EP EP09792581.2A patent/EP2328551B1/en active Active
- 2009-09-16 CN CN2009801371097A patent/CN102176898A/zh active Pending
- 2009-09-16 PL PL11191277T patent/PL2425815T3/pl unknown
- 2009-09-16 PL PL09792581T patent/PL2328551T3/pl unknown
- 2009-09-16 WO PCT/US2009/057065 patent/WO2010033528A1/en not_active Ceased
- 2009-09-16 AU AU2009293400A patent/AU2009293400B2/en active Active
- 2009-09-16 US US12/560,509 patent/US20100076045A1/en not_active Abandoned
- 2009-09-16 NO NO11191277A patent/NO2425815T3/no unknown
- 2009-09-16 RU RU2011115211/15A patent/RU2521258C2/ru active
- 2009-09-16 HU HUE11191277A patent/HUE037933T2/hu unknown
- 2009-09-16 SI SI200931783T patent/SI2425815T1/en unknown
- 2009-09-16 JP JP2011527909A patent/JP5739809B2/ja active Active
- 2009-09-16 CN CN201510086562.7A patent/CN104688682A/zh active Pending
- 2009-09-16 ES ES09792581.2T patent/ES2592503T3/es active Active
- 2009-09-16 DK DK11191277.0T patent/DK2425815T3/da active
- 2009-09-16 BR BRPI0919199A patent/BRPI0919199B8/pt active IP Right Grant
- 2009-09-16 KR KR1020117008617A patent/KR101682924B1/ko active Active
2011
- 2011-02-22 ZA ZA2011/01398A patent/ZA201101398B/en unknown
2014
- 2014-06-11 US US14/302,122 patent/US20140294970A1/en not_active Abandoned
- 2014-12-11 JP JP2014250576A patent/JP2015052020A/ja not_active Withdrawn
2016
- 2016-12-02 JP JP2016234682A patent/JP2017043637A/ja not_active Withdrawn
2017
- 2017-04-21 US US15/493,232 patent/US20170216228A1/en not_active Abandoned
2018
- 2018-01-05 CY CY20181100015T patent/CY1119740T1/el unknown
- 2018-01-10 HR HRP20180050TT patent/HRP20180050T1/hr unknown
2022
- 2022-01-14 AR ARP220100069A patent/AR124648A2/es unknown

Also Published As

Publication number	Publication date
BRPI0919199A2 (pt)	2015-12-15
PT2328551T (pt)	2016-09-22
EP2425815A1 (en)	2012-03-07
UY32095A (es)	2010-01-29
CN104688682A (zh)	2015-06-10
RU2521258C2 (ru)	2014-06-27
JP2015052020A (ja)	2015-03-19
ES2657455T3 (es)	2018-03-05
JP2012503003A (ja)	2012-02-02
CY1119740T1 (el)	2018-09-05
CL2009001856A1 (es)	2010-12-31
HUE037933T2 (hu)	2018-09-28
BRPI0919199B8 (pt)	2021-05-25
US20170216228A1 (en)	2017-08-03
ES2592503T3 (es)	2016-11-30
US20100076045A1 (en)	2010-03-25
CA2736106A1 (en)	2010-03-25
JP5739809B2 (ja)	2015-06-24
HRP20180050T1 (hr)	2018-02-09
ZA201101398B (en)	2012-04-25
JP2017043637A (ja)	2017-03-02
EP2328551A1 (en)	2011-06-08
WO2010033528A1 (en)	2010-03-25
AU2009293400B2 (en)	2015-05-07
MX2011002494A (es)	2011-04-07
BRPI0919199B1 (pt)	2020-10-27
US20140294970A1 (en)	2014-10-02
PT2425815T (pt)	2018-01-31
KR101682924B1 (ko)	2016-12-06
PL2425815T3 (pl)	2018-03-30
EP2328551B1 (en)	2016-06-15
CA2736106C (en)	2016-08-16
NO2425815T3 (da)	2018-03-24
PL2328551T3 (pl)	2017-04-28
SI2425815T1 (en)	2018-02-28
MX348204B (es)	2017-05-30
KR20110054055A (ko)	2011-05-24
TWI580441B (zh)	2017-05-01
AR124648A2 (es)	2023-04-19
AR073597A1 (es)	2010-11-17
CN102176898A (zh)	2011-09-07
EP2425815B1 (en)	2017-10-25
AU2009293400A1 (en)	2010-03-25
HK1152258A1 (zh)	2012-02-24
LT2425815T (lt)	2018-01-25
TW201014612A (en)	2010-04-16
RU2011115211A (ru)	2012-10-27

Publication	Publication Date	Title
DK2425815T3 (da)	2018-01-29	Stabiliseret farmaceutisk submikrometersuspensioner og fremgangsmåder til fremstilling deraf
CY1122617T1 (el)	2020-10-14	Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι
WO2009117410A3 (en)	2009-12-17	Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques
MY159156A (en)	2016-12-15	Antibody formulation
MX343016B (es)	2016-10-20	Polimeros anclados que se usan para potenciar la estabilidad de fluidos de microemulsion.
EP3679924A3 (en)	2020-07-29	Formulation comprising particles
WO2009012303A3 (en)	2010-08-12	Therapeutic stable nanoparticles
TNSN08284A1 (en)	2009-10-30	Masking the taste of powders
WO2007027941A3 (en)	2007-04-26	Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007118653A3 (de)	2008-06-12	Nanopartikel, enthaltend nicotin und/oder cotinin, dispersionen und die verwendung derselben
WO2010096733A3 (en)	2010-11-18	Luminescent porous silicon nanoparticles, methods of making and using same
WO2006108405A3 (de)	2007-02-01	Nanopartikel-wirkstoff-konjugate
WO2015152693A3 (ko)	2015-11-26	신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
WO2007047253A3 (en)	2009-04-30	Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2010057214A3 (en)	2010-07-15	Nanoparticles and porous particles and methods of making the same
DK1720949T3 (da)	2012-07-02	Fremgangsmåde til forbedring af lagerstabiliteten for kompositpartikeldispersioner
WO2008106571A3 (en)	2008-11-27	Sustained release parenteral formulations of buprenorphine
SI1731138T1 (sl)	2016-06-30	Fina disperzija slabo topljivega zdravila in postopek za njeno izdelavo
NO20076120L (no)	2007-11-27	Stabile nanopartikkelformuleringer
WO2009052942A3 (de)	2009-07-09	Stabilisierung von hydrophoben proteintherapeutika
WO2010120872A3 (en)	2011-03-24	Method of decreasing pro-adam10 secretase and/or beta secretase levels
PH12013502521A1 (en)	2014-01-20	Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation
MX2017003049A (es)	2017-05-23	Administracion dirigida de farmacos hidrofilicos.
IL275334A (en)	2020-07-30	Solid lipid nanoparticles for intracellular release of active substances and a method for their production
MY148088A (en)	2013-02-28	Stable nanoparticle formulations